In the BioHarmony Drug Report Database

"Preview" Icon

Alendronic acid

Binosto, Fosamax, Adrovance, Alendronate sodium and colecalciferol, MSD, Fosavance, Vantavo (alendronic acid) is a small molecule pharmaceutical. Alendronic acid was first approved as Binosto on 1995-09-29. It is used to treat extramammary paget disease and postmenopausal osteoporosis in the USA. It has been approved in Europe to treat postmenopausal osteoporosis. The pharmaceutical is active against farnesyl pyrophosphate synthase. Fosamax’s patent is valid until 2031-12-05 (FDA).

 

Trade Name

 

Adrovance, Alendronate sodium and colecalciferol, MSD, Fosavance, Vantavo
 

Common Name

 

alendronic acid
 

ChEMBL ID

 

CHEMBL870
 

Indication

 

extramammary paget disease, postmenopausal osteoporosis
 

Drug Class

 

Calcium metabolism regulators

Image (chem structure or protein)

Alendronic acid structure rendering